RCT | Fluvoxamine no better than placebo in outpatients with mild to moderate COVID-19

Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial – JAMA

Editorial: Lack of Benefit of Fluvoxamine for COVID-19 – JAMA

Author Interview: Fluvoxamine vs Placebo and Time to Sustained Recovery From Mild or Moderate COVID-19 – JAMA

Commentary: Trial finds that fluvoxamine doesn’t speed COVID recovery – CIDRAP

Commentary on Twitter

Among outpatients with mild to moderate #COVID19, treatment with 50 mg of fluvoxamine twice daily for 10 days, compared with placebo, did not improve time to sustained recovery. https://t.co/4QgBssqFSU pic.twitter.com/RMZ6mqlx6u

— JAMA (@JAMA_current) January 12, 2023